**Disparities Part 2: Right Care Heart Attack & Stroke Prevention (11.13.23): Tackling Racial and Ethnic Disparities to Improve Outcomes: The ABCs of Risk Evaluation for Coronary Artery Disease and Diabetes Mellitus in the South Asian Population**

December 4, 2024 – January 4, 2027

**Error! Unknown op code for conditional.**

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Radiological Sciences, Other

**Activity Objectives**

1 Understand the relationship between markers of obesity and insulin resistance.

2 Review the role of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), lipoprotein(a) (Lp(a)), homocysteine (Hcy), and high-sensitivity C-reactive protein (hs-CRP), with metabolic syndrome, and severity of coronary arteriosclerosis.

2 Understand the role of dysmetabolism and dyslipidemia as drivers of coronary arteriosclerosis.

3 Understand the potential relationship between the epidemiology of diabetes and coronary artery disease.

3 Review the role of Apolipoprotein B (Apo B) and non-HDL cholesterol/Apo B ratio in coronary arteriosclerosis.

4 Introduce triglyceride to HDL cholesterol ratio as a marker of insulin resistance.

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



ABIM
CME
MOC
Accredited

ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**MOC Statement(s)**

ABIM
CME
MOC
AccreditedSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ABMS

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director | Nothing to disclose - 10/23/2024 |
| Karen M Sky, MD, FACP, FACR | Activity Coordinator | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Planning Commitee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 11/08/2024 |
| Jan Hirsch, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| William Bommer, MD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Cesar Molina, MD | Faculty | Nothing to disclose - 12/02/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.